Overview
Acetyl Hexapeptide-8 is a synthetic peptide composed of six amino acids — glutamic acid, glutamic acid, methionine, glutamine, arginine, and arginine — with an acetyl group attached to its N-terminus, giving it the sequence Ac-Glu-Glu-Met-Gln-Arg-Arg. It is a cosmetic research peptide that has attracted scientific interest for its potential interactions with skin-related biological processes, particularly in the context of aging research. Studies examining this peptide have explored topics such as transdermal delivery mechanisms, including the use of dissolving microneedles and cooling-assisted devices to investigate how it penetrates the skin barrier in ex vivo tissue models. It is also being studied alongside other active compounds in formulations designed to examine changes in skin biomarkers and texture at a cellular level. Acetyl Hexapeptide-8 is intended strictly for laboratory and research purposes and is not approved for human use or consumption.
Research & Bioactivity
Researchers have studied Acetyl Hexapeptide-8 primarily in the context of skin aging biology, with particular interest in its potential effects on markers associated with facial muscle contraction and extracellular matrix dynamics. Ex vivo studies using human-derived skin tissue models have examined this peptide's interaction with skin biomarkers related to aging, often in combination with other compounds such as dipeptide diaminobutyroyl benzylamide diacetate, gluconolactone, and niacinamide, to assess changes in wrinkle appearance and skin texture at a cellular level. Research has also investigated Acetyl Hexapeptide-8 as a candidate ingredient in transdermal delivery systems, including dissolving microneedle platforms composed of hyaluronic acid and polyvinyl alcohol matrices, to study how the peptide can be stabilized and transported across the skin barrier into deeper tissue layers. Additional studies have explored delivery enhancement technologies — such as cooling-assisted devices and fluorous penetrating peptide carriers — to better understand the permeability challenges that peptides like Acetyl Hexapeptide-8 face when applied topically. Collectively, this body of research situates Acetyl Hexapeptide-8 within the broader scientific investigation of peptide-based compounds and their behavior in skin biology models.
Published Research
Ex Vivo Evaluation of Skin Permeability Enhancement Using TargetCool in Human-Derived Skin Tissue Models.
Yi KH, Kim JH, Heo CY, Seo SB, Kim GH — 2026
BACKGROUND: The stratum corneum presents a significant barrier to transdermal delivery. TargetCool is a cooling-assisted delivery device developed to enhance skin penetration, with potential synergistic effects when combined with microneedling systems such as the Turtle pin (0.5 mm) and MTS (1.5 mm). OBJECTIVE: This study aimed to evaluate the effect of TargetCool on the permeability of Acetyl Hexapeptide-8-FITC in an ex vivo human skin model, comparing its performance alone and in combination with microneedling devices. METHODS: Facial skin samples from Korean female donors aged 50 to 70 years were prepared into 2 × 2 cm sections and assigned to 6 groups: control (topical application only), Turtle pin 0.5 mm, MTS 1.5 mm, Turtle pin 0.5 mm plus TargetCool, MTS 1.5 mm plus TargetCool, and TargetCool alone. Samples were cultured for 24 hours in a Transwell system following treatment with Acetyl Hexapeptide-8-FITC, then processed for H&E and DAPI staining. Optical and fluorescence microscopy were used to assess tissue structure, fluorescence intensity, and penetration depth, with quantitative analysis performed using ImageJ. RESULTS: No structural damage was observed in any group. Compared with the control, fluorescence intensity increased by 504% with Turtle pin, 700% with MTS, 1272% with Turtle pin plus TargetCool, 1000% with MTS plus TargetCool, and 492% with TargetCool alone. Penetration depth increased by 19.01%, 33.10%, 36.88%, 47.75%, and 35.86%, respectively. CONCLUSION: TargetCool, particularly in combination with microneedling, substantially enhanced the skin penetration and depth of Acetyl Hexapeptide-8-FITC in ex vivo human skin without inducing structural damage. These findings support its potential clinical application in improving transdermal delivery for dermatologic and aesthetic treatments.
The effect of a serum containing acetyl hexapeptide-8, dipeptide diaminobutyroyl benzylamide diacetate and gluconolactone on skin biomarkers, wrinkles and skin texture: Ex vivo and clinical studies.
Zhu M, He X, Zhu Z, Lynch S, Wang H, et al. — 2026
OBJECTIVE: This study aimed to explore the anti-skin aging efficacy of a novel serum containing acetyl hexapeptide-8, dipeptide diaminobutyroyl benzylamide diacetate, gluconolactone, niacinamide and laminaria extract through one ex-vivo study and two clinical studies. METHODS: In ex-vivo study, skin samples were exposed to the serum (Formula 1) and its active ingredient combinations (Formula 2). Biomarkers including matrix metalloproteinase-1, elastic fibres and collagen types I, III, IV and XVII content were analyzed to evaluate the efficacy. In clinical study 1 (n = 50), the Formula 1's efficacy in reducing static wrinkles and improving skin quality was examined, while study 2 (n = 42) focused on its efficacy against dynamic wrinkles. RESULTS: Formula 1 significantly increased levels of anti-aging biomarkers including elastic fibres, collagen fibres, etc. Meanwhile, Formula 1 significantly improved static wrinkle appearance within the first week, with mean clinical scoring from 35% to 69% for various types of wrinkles after 12 weeks of use (all p < 0.001). The clinical scoring for dynamic wrinkles improved by 10%-13% (all p < 0.001). Additionally, significant improvements were observed in skin quality, indicated by clinical scoring changes of smoothness (30%), radiance (27%), skin pore (43%), elasticity (33%) and firmness (36%) (all p < 0.001). CONCLUSION: The serum demonstrates significant anti-aging effects, effectively improving static and dynamic wrinkles and skin quality.
Thermostable hyaluronic acid-based dissolving microneedles with high-loading capacity: design, optimization, and transdermal delivery of anti-aging ingredients.
Feng M, Wu C, Jiang Y, Zhao C — 2026
This study developed a thermostable, high-loading dissolving microneedle (DMN) system for the transdermal delivery of anti-aging ingredients, 3-O-ethyl ascorbic acid (EAC) and acetyl hexapeptide-8 (AH-8). By using a composite matrix of hyaluronic acid (HA) and polyvinyl alcohol (PVA) in a 3:2 ratio and optimizing a two-step vacuum-assisted micromolding process, we successfully addressed key fabrication challenges, reducing drying time to 2 h and eliminating structural defects. A split-needle design further increased drug loading, reaching 40% for EAC and 20% for AH-8. The resulting DMNs showed excellent mechanical properties, skin penetration efficiency, and biocompatibility in human subjects. In vitro permeation studies using Bama miniature pig skin revealed release profiles influenced by drug-polymer interactions. Despite these differences, both compounds achieved higher cumulative transdermal delivery (EAC: 17.25%; AH-8: 11.29%) than their aqueous solutions. In a UV/D-galactose-induced photoaging mouse model, both EAC-DMNs and AH-8-DMNs significantly reduced visible signs of aging, including wrinkles, skin laxity, and erythema. They also improved skin elasticity and hydration, reversed pathological thickening, and restored oxidative balance by increasing SOD activity and lowering MDA levels. This work provides a scalable, biocompatible, and effective DMN platform, supporting its potential for clinical anti-aging applications.
Fluorous oligoarginines as supra-enhancers for intracellular and transdermal peptide delivery.
Rong G, Fan Q, Chen K, Cheng Y, Hu J — 2026
Peptides are increasingly recognized as important therapeutics due to their specificity and potency. However, their clinical application is often hindered by numerous barriers, including low bioavailability, poor cell membrane and tissue penetration. To address these limitations, we developed a library of fluorous penetrating peptides and identified fluorinated hexa-arginine (FR6) as a super-enhancer for cell and tissue penetration. FR6 markedly enhances the intracellular delivery of a variety of peptides by improving membrane permeability, facilitating their uptake across diverse cell types. It greatly improves the penetration of bioactive peptides in 3D tumor spheroids, allowing for improved therapeutic efficacy. More importantly, FR6 demonstrates remarkable potential for transdermal delivery of peptide drugs, effectively enhancing the penetration of peptides like acetyl hexapeptide-8 for treating UVB-induced skin photoaging. Our findings underscore the use of FR6 as a super-enhancer in overcoming multiple physiological barriers during cell, tissue and transdermal delivery.
Oligomeric hyaluronic acid-modified liposomes effectively improved skin permeability and anti-ageing activity of ellagic acid.
Yang X, Miao K, Chen Z, Meng Y, Xiang J, et al. — 2025
To overcome natural skin barrier, deliver ellagic acid (EA) to the dermis, and promote its anti-ageing efficacy, oligomeric hyaluronic acid (HA) modified EA-loaded liposomes (EA-HA-L) were constructed via self-synthesized different molecular weights of HA linked cholesterol (HA-Chol), and then the effect of HA molecular weight on the skin permeability of EA was explored to clarify the optimal molecular weight of HA with best transdermal delivery effectiveness. Finally, a series of in vitro and in vivo experiments were conducted to survey the transdermal mechanism, skin irritation, antioxidant, anti-photo ageing and antiwrinkle effects of EA-loaded liposomes modified with the optimal molecular weight of HA. The results showed that EA-HA-L had less than 200 nm particle size and high encapsulation efficiency. Among them, 5 kDa of oligomeric HA-modified liposomes (EA-HA5k-L) maximized the skin penetration and retention of EA and promoted the distribution width of EA in the skin far beyond the thickness of the epidermal layer, indicating its good ability to deliver EA to the dermis. EA-HA5k-L displayed uniformly sized nanosphere morphology and slow-release behavior in neutral and acidic environments that simulated skin. The transdermal mechanism of EA-HA5k-L was proven to be related to the loosening of the stratum corneum, reduction of calcium adhesion proteins, and recognition of CD44 receptor. EA-HA5k-L had no irritant effect on the chicken embryo chorioallantoic membrane, with an irritant index close to 0.9% NaCl. EA-HA5k-L not only improved the clearance rate of EA on DPPH and hydroxyl radicals but also elevated its inhibition effect on elastase. Significantly, compared to free EA and EA-loaded liposomes without oligomeric HA modification (EA-L), EA-HA5k-L significantly increased the cellular uptake of EA through receptor-mediated endocytosis, and effectively blocked the increase in metalloproteinase-1 (MMP-1) content and decrease in type I collagen content induced by UVB in human dermal fibroblasts (HDFs), demonstrating better anti-photo ageing effectiveness. Moreover, EA-HA5k-L upregulated the relative expression of the elastin gene and three types of type I collagen gene (col1a1a, col1a1b, and col1a2) in zebrafish, and its expression promotion rates in col1a1b, col1a2 and elastin were remarkably higher than those of free EA, EA-L, and acetyl hexapeptide-8 as positive control. Conclusively, EA-HA5k-L ameliorated the anti-ageing effectiveness of EA due to the successful transdermal delivery and efficient cellular uptake, and 5 kDa of oligomeric HA-modified liposomes may be a promising transdermal delivery carrier to overcome skin barrier and upgrade the application prospects of EA in anti-skin ageing.